Eli Lilly hustles up an impressive set of pivotal data for their $8B Loxo drug — as rival nips at their heels
Eli Lilly’s $8 billion bet on Loxo has paid off today with a convincing set of lung cancer data for selpercatinib (LOXO-292) that will keep the typically sluggish pharma giant at least one step ahead of rival Blueprint Medicines as they both look to make a beeline to the FDA.
Researchers for the company turned out at the 2019 World Conference on Lung Cancer to tout an impressive 68% response rate for the 105 evaluable RET fusion-positive patients in their latest study of this drug — which falls right in line with their earlier results. Their most recent cut of the data available from treatment-resistant patients with an average of 3 prior lines of therapy demonstrated 20.3 months of median duration with progression-free survival of 18.4 months in the single-arm study — though that set of data is still maturing.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.